首頁 > 市場調查報告書 > 製藥

肝素市場規模、佔有率和成長分析（按產品類型、給藥途徑、成分、供應、治療方法領域、規格、類型、包裝和地區分類）－2026-2033年產業預測

市場調查報告書

商品編碼

1899116

肝素市場規模、佔有率和成長分析（按產品類型、給藥途徑、成分、供應、治療方法領域、規格、類型、包裝和地區分類）－2026-2033年產業預測

Heparin Market Size, Share, and Growth Analysis, By Product Type, By Mode of Administration, By Ingredient, By Availability, By Treatment, By Therapeutics, By Strength, By Type, By Container, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月19日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，全球肝素市場規模將達到 75.1 億美元，到 2025 年將達到 77.1 億美元，到 2033 年將達到 94.6 億美元，預測期（2026-2033 年）的複合年成長率為 2.6%。

全球肝素市場是醫療保健和製藥業的重要組成部分，主要集中在動物性抗凝血劑領域。心血管疾病病例增加、人口老化以及外科手術數量上升導致抗凝血劑需求不斷成長，這是推動市場成長的主要因素。此外，與文明病相關的健康問題和住院率上升也促進了對肝素產品的需求。持續進行研發工作，開發先進的肝素遞送系統，也對市場成長產生了正面影響。然而，監管審查力度加大、市場競爭加劇以及肝素誘發的血小板減少性疾病併發症潛在併發症等挑戰可能會阻礙市場成長。儘管存在這些障礙，但生物相似藥、創新藥物遞送系統以及新興市場的成長等機遇，仍為市場帶來了可觀的前景。

全球肝素市場促進因素

全球肝素市場主要受心血管疾病高發生率的推動，心血管疾病是全球死亡和殘疾的主要原因。心肌梗塞、心房顫動和中風等疾病會顯著增加血栓性栓塞症的風險，增加對肝素及類似抗凝血劑的需求。此外，肺動脈栓塞（PE）和深層靜脈栓塞症（DVT）的發病率上升也推動了對肝素的需求，因為肝素已成為治療這些疾病的標準治療方法。這些健康挑戰共同確保了對有效抗凝血療法的持續需求，從而支撐了市場成長。

限制全球肝素市場的因素

全球肝素市場面臨許多限制因素，其中最主要的是肝素治療可能帶來的副作用，尤其是出血風險，這會導致病人焦慮和醫護人員謹慎用藥。此外，諸如肝素誘發的血小板減少性疾病（HIT）等疾病也會帶來嚴重風險，並可能削弱人們對治療通訊協定的信心。而且，使用未分級肝素需要密切監測活化部份凝血活酵素時間（aPTT），這會使治療方案更加複雜，並需要更精細的管理流程，尤其是在門診環境中。這些因素共同構成了肝素市場的挑戰。

全球肝素市場趨勢

目前，全球肝素市場正經歷生物相似藥研發和應用的強勁成長趨勢。隨著原廠肝素製劑專利的到期，經濟高效的生物相似藥的出現為醫療機構提供了一種在不影響患者照護品質的前提下有效控制成本的可行方案。這種轉變在歐洲和北美等關鍵地區尤其明顯，相關人員越來越重視藥品採購中的可負擔性。對生物相似藥日益成長的關注反映了市場環境的變化，其特徵是治療方案的競爭加劇和創新，同時也凸顯了市場向更永續、更公平的醫療保健解決方案轉變的趨勢。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Opocrin SpA（Italy）
Baxter International Inc.（US）
Pfizer Inc.（US）
Bioiberica SAU（Spain）
Fresenius SE & Co. KGaA（Germany）
Hebei Changshan Biochemical Pharmaceutical Co., Ltd.（China）
B. Braun SE（Germany）
Dr. Reddy's Laboratories Ltd.（India）
LEO Pharma A/S（Denmark）
Aspen Holdings（South Africa）
Gland Pharma（India）
Hikma Pharmaceuticals（United Kingdom）
Techdow USA（US）
Viatris Inc.（US）
Biological E. Limited（India）
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.（China）
Faran Shimi Pharmaceutical Company（Iran）
Octapharma AG（Switzerland）
Kamada Ltd.（Israel）

結論與建議

簡介目錄

Product Code: SQMIG35H2166

Global Heparin Market size was valued at USD 7.51 Billion in 2024 and is poised to grow from USD 7.71 Billion in 2025 to USD 9.46 Billion by 2033, growing at a CAGR of 2.6% during the forecast period (2026-2033).

The global heparin market is a crucial segment within the healthcare and pharmaceutical industries, focusing on anticoagulant medications derived from animal tissues. It is primarily fueled by rising cardiovascular disease cases, an increasing aging population, and a higher volume of surgical procedures, leading to greater demand for anticoagulants. Additionally, lifestyle-related health issues heighten the need for heparin products, supported by increasing hospitalization rates. Ongoing research and development efforts aimed at creating advanced heparin delivery systems also contribute positively to market growth. However, challenges such as regulatory scrutiny, intense market competition, and potential complications like heparin-induced thrombocytopenia may hinder growth. Despite these obstacles, the market shows promise through opportunities in biosimilars, innovative drug delivery systems, and growth in emerging markets.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Heparin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Heparin Market Segments Analysis

Global Heparin Market is segmented by Product Type, Mode of Administration, Source, Ingredient, Availability, Treatment, Therapeutics, Strength, Type, Container, Packaging, Distribution Channel, Application, End User and region. Based on Product Type, the market is segmented into Unfractionated Heparin, Low Molecular Weight Heparin (LMWH) and Ultra-Low Molecular Weight Heparin (ULMWH). Based on Mode of Administration, the market is segmented into Oral Administration and Parenteral Administration. Based on Source, the market is segmented into Bovine and Porcine. Based on Ingredient, the market is segmented into Sodium, Calcium and Others. Based on Availability, the market is segmented into Raw and Processed. Based on Treatment, the market is segmented into Deep Vein Thrombosis, Pulmonary Embolism, Arterial Thromboembolism and Others. Based on Therapeutics, the market is segmented into Cardiovascular, Respiratory, Oncology, Nephrology, CNS and Others. Based on Strength, the market is segmented into 10 -1000 Unit, 1000 -5000 Unit, 5000- 25000 Unit and Others. Based on Type, the market is segmented into Generics and Brands. Based on Container, the market is segmented into Bottles, Bags, Vials and Others. Based on Packaging, the market is segmented into Glass and Plastic. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Drug Store, Online Pharmacy and Others. Based on Application, the market is segmented into Pre-Surgical Procedures, Post-Surgical Procedures, Kidney Dialysis, Diagnostic Tests and Others. Based on End User, the market is segmented into Hospitals, Clinics, Homecare, Ambulatory Surgical Centres and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Heparin Market

The global Heparin market is significantly driven by the prevalence of cardiovascular diseases, which are the primary causes of mortality and disability worldwide. Conditions such as heart attacks, atrial fibrillation, and strokes greatly elevate the risk of thromboembolic disorders, thereby amplifying the need for heparin and similar anticoagulants. Additionally, the increasing incidence of pulmonary embolism (PE) and deep vein thrombosis (DVT) further fuels the demand for heparin, as it is considered the standard of care for managing these conditions. This combination of health challenges ensures a sustained requirement for effective anticoagulant therapies, supporting market growth.

Restraints in the Global Heparin Market

The global heparin market faces significant restraints due to the potential side effects associated with heparin therapy, particularly the risk of bleeding, which can lead to apprehension among patients and caution among healthcare providers. Additionally, conditions such as heparin-induced thrombocytopenia (HIT) pose serious risks that can undermine confidence in treatment protocols. Furthermore, the requirement for meticulous monitoring of activated partial thromboplastin time (aPTT) when using unfractionated heparin complicates the treatment regimen, particularly in outpatient settings, leading to more complex management routines. These factors collectively contribute to the challenges faced by the heparin market.

Market Trends of the Global Heparin Market

The Global Heparin market is currently witnessing a strong trend towards the development and adoption of biosimilars. As patents for original heparin formulations expire, the emergence of cost-effective biosimilars presents a viable alternative, enabling healthcare providers to manage costs while ensuring patient care remains uncompromised. This shift is particularly pronounced in major regions such as Europe and North America, where stakeholders are increasingly prioritizing affordability in drug procurement. The growing emphasis on these biosimilars underscores a broader market shift towards more sustainable and equitable healthcare solutions, reflecting an evolving landscape defined by enhanced competition and innovation in therapeutic options.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies
Technological Advancement

Global Heparin Market Size by Product Type & CAGR (2026-2033)

Market Overview
Unfractionated Heparin
Low Molecular Weight Heparin (LMWH)
Ultra-Low Molecular Weight Heparin (ULMWH)

Global Heparin Market Size by Mode of Administration & CAGR (2026-2033)

Market Overview
Oral Administration
Parenteral Administration

Global Heparin Market Size by Source & CAGR (2026-2033)

Market Overview
Bovine
Porcine

Global Heparin Market Size by Ingredient & CAGR (2026-2033)

Market Overview
Sodium
Calcium
Others

Global Heparin Market Size by Availability & CAGR (2026-2033)

Market Overview
Raw
Processed

Global Heparin Market Size by Treatment & CAGR (2026-2033)

Market Overview
Deep Vein Thrombosis
Pulmonary Embolism
Arterial Thromboembolism
Others

Global Heparin Market Size by Therapeutics & CAGR (2026-2033)

Market Overview
Cardiovascular
Respiratory
Oncology
Nephrology
CNS
Others

Global Heparin Market Size by Strength & CAGR (2026-2033)

Market Overview
10 -1000 Unit
1000 -5000 Unit
5000- 25000 Unit
Others

Global Heparin Market Size by Type & CAGR (2026-2033)

Market Overview
Generics
Brands

Global Heparin Market Size by Container & CAGR (2026-2033)

Market Overview
Bottles
Bags
Vials
Others

Global Heparin Market Size by Packaging & CAGR (2026-2033)

Market Overview
Glass
Plastic

Global Heparin Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital Pharmacy
Retail Pharmacy and Drug Store
Online Pharmacy
Others

Global Heparin Market Size by Application & CAGR (2026-2033)

Market Overview
Pre-Surgical Procedures
Post-Surgical Procedures
Kidney Dialysis
Diagnostic Tests
Others

Global Heparin Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals
Clinics
Homecare
Ambulatory Surgical Centres
Others

Global Heparin Market Size & CAGR (2026-2033)

North America (Product Type, Mode of Administration, Source, Ingredient, Availability, Treatment, Therapeutics, Strength, Type, Container, Packaging, Distribution Channel, Application, End User)
- US
- Canada
Europe (Product Type, Mode of Administration, Source, Ingredient, Availability, Treatment, Therapeutics, Strength, Type, Container, Packaging, Distribution Channel, Application, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product Type, Mode of Administration, Source, Ingredient, Availability, Treatment, Therapeutics, Strength, Type, Container, Packaging, Distribution Channel, Application, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product Type, Mode of Administration, Source, Ingredient, Availability, Treatment, Therapeutics, Strength, Type, Container, Packaging, Distribution Channel, Application, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Product Type, Mode of Administration, Source, Ingredient, Availability, Treatment, Therapeutics, Strength, Type, Container, Packaging, Distribution Channel, Application, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Opocrin S.p.A. (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Baxter International Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bioiberica S.A.U. (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fresenius SE & Co. KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
B. Braun SE (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dr. Reddy's Laboratories Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
LEO Pharma A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aspen Holdings (South Africa)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gland Pharma (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hikma Pharmaceuticals (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Techdow USA (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biological E. Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Faran Shimi Pharmaceutical Company (Iran)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Octapharma AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kamada Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments